Correlation of Serum Alanine Aminotransferase with Clinical Outcomes in Acute Ischemic Cerebrovascular Disease

doi:10.3969/j.issn.1673-5765.2023.02.008

Abstract

Abstract: Objective To investigate the correlation of serum alanine aminotransferase (ALT) level with poor clinical outcomes in acute ischemic stroke (AIS) or transient ischemic attack (TIA) patients.
Methods Patients with AIS or TIA and having serum ALT level < 120 U/L from the China National Stroke RegistryⅡ(CNSRⅡ) were included in the current analysis.The clinical outcomes included recurrent stroke (including ischemic stroke, intracranial hemorrhage and subarachnoid hemorrhage), composite endpoint events, all-cause death and poor functional outcome within one year. Composite endpoint included recurrent stroke and all-cause death. Poor functional outcome was defined as a mRS score of 3-6. Multivariable logistic regression analysis was used to evaluate the correlation of serum ALT level with the risk of 1-year all-cause death, recurrent stroke, composite endpoint and poor functional outcome, according to the sex-specific quintile of serum ALT level.
Results A total of 17 178 patients were included, with a mean age of 64.8±11.9 years old and 6368 females (37.1%). Compared with the lowest ALT (corresponding to the lowest serum ALT level), the adjusted odds ratio with 95% confidence interval of the highest quintile were 0.55 (0.43-0.70) for all-cause mortality (P＜0.01）, 0.61 (0.45-0.83) for recurrent stroke (P＜0.01）, 0.62 (0.49-0.77) for composite endpoint (P＜0.01）, and 0.67 (0.56-0.80) for poor functional outcome (P＜0.01）. There was no significant interaction of ALT with age, sex, diabetes, dyslipidemia and alcohol consumption for all outcomes.
Conclusions The serum ALT level may be negatively correlated with the risk of 1-year all-cause mortality, recurrent stroke, and poor functional outcome in AIS or TIA patients.

Key words: Acute ischemic stroke; Alanine aminotransferase; Risk factor; Prognosis; Recurrent stroke

摘要： 目的探索血清丙氨酸转氨酶（alanine aminotransferase，ALT）水平与急性缺血性脑血管病不良临床结局的关系。
方法以中国国家卒中登记研究Ⅱ中丙氨酸转氨酶（alanine aminotransferase，ALT）水平<120 U/L的急性缺血性卒中或TIA患者为研究对象。随访研究对象的1年全因死亡、复发性卒中（包括缺血性卒中、脑出血及蛛网膜下腔出血）、复合终点事件和不良功能结局，其中复合终点事件包括复发性卒中和全因死亡，不良功能结局定义为mRS 3～6分。根据入组患者的血清ALT水平由低到高进行ALT五分位数分层（Q1～Q5），采用多因素logistic回归分析评估血清ALT水平与1年全因死亡、卒中复发、复合终点事件和不良功能结局的相关性。
结果研究共纳入17 178例患者，平均年龄（64.8±11.9）岁，女性6368例（37.1%）。多因素logistic回归分析结果显示，相对于ALT最低五分位数患者，最高五分位数患者1年内全因死亡风险降低45%（OR 0.55，95%CI 0.43～0.70，P＜0.01）、卒中复发风险降低39%（OR 0.61，95%CI 0.45～0.83，
P＜0.01）、复合终点事件风险降低38%（OR 0.62，95%CI 0.49～0.77，P＜0.01），不良功能结局风险降低33%（OR 0.67，95%CI 0.56～0.80，P＜0.01）。年龄、性别、糖尿病、血脂异常和饮酒对ALT与各结局指标之间的相关性无交互作用。
结论血清ALT水平与AIS或TIA患者1年全因死亡率、卒中复发、复合终点事件和功能不良结局的风险呈负相关。

关键词: 急性缺血性卒中; 丙氨酸转氨酶; 危险因素; 预后; 卒中复发

ZONG Lixia, WANG Xianwei, LI Zixiao, ZHAO Xingquan, LIU Liping, LI Hao, MENG Xia, WANG Yilong, WANG Yongjun.

Correlation of Serum Alanine Aminotransferase with Clinical Outcomes in Acute Ischemic Cerebrovascular Disease

[J]. Chinese Journal of Stroke, 2023, 18(02): 185-193.

宗黎霞, 王献伟, 李子孝, 赵性泉, 刘丽萍, 李昊, 孟霞, 王伊龙, 王拥军. 血清丙氨酸转氨酶与急性缺血性脑血管病临床结局的相关性研究[J]. 中国卒中杂志, 2023, 18(02): 185-193.

References

[1] GOESSLING W，MASSARO J M，VASAN R S，et al. Aminotransferase levels and 20-year risk of metabolic syndrome，diabetes，and cardiovascular disease[J]. Gastroenterology，2008，135（6）：1935-1944.
[2] SCHNEIDER A L，LAZO M，NDUMELE C E，et al. Liver enzymes，race，gender and diabetes risk：The atherosclerosis risk in communities（ARIC）study[J]. Diabet Med，2013，30（8）：926-933.
[3] HANLEY A J，WILLIAMS K，FESTA A，et al. Liver markers and development of the metabolic syndrome：the insulin resistance atherosclerosis study[J]. Diabetes，2005，54（11）：3140-3147.
[4] SCHINDHELM R K，DEKKER J M，NIJPELS G，et al. Alanine aminotransferase predicts coronary heart disease events：a 10-year follow-up of the hoorn study[J]. Atherosclerosis，2007，191（2）：391-396.
[5] FORD I，MOOIJAART S P，LLOYD S，et al. The inverse relationship between alanine aminotransferase in the normal range and adverse cardiovascular and non-cardiovascular outcomes[J]. Int J Epidemiol，2011，40（6）：1530-1538.
[6] RUHL C E，EVERHART J E. The association of low serum alanine aminotransferase activity with mortality in the us population[J]. Am J Epidemiol，2013，178（12）：1702-1711.
[7] KUNUTSOR S K，BAKKER S J，KOOTSTRA-ROS J E，et al. Inverse linear associations between liver aminotransferases and incident cardiovascular disease risk：the PREVEND study[J]. Atherosclerosis，2015，243（1）：138-147.
[8] KIM H C，KANG D R，NAM C M，et al. Elevated serum aminotransferase level as a predictor of intracerebral hemorrhage：Korea medical insurance corporation study[J]. Stroke，2005，36（8）：1642-1647.
[9] KUNUTSOR S K，APEKEY T A，KHAN H. Liver enzymes and risk of cardiovascular disease in the general population：a meta-analysis of prospective cohort studies[J]. Atherosclerosis，2014，236（1）：7-17.
[10] LI Z X，WANG C J，ZHAO X Q，et al. China National Stroke Registries. Substantial progress yet significant opportunity for improvement in stroke care in China[J]. Stroke，2016，47（11）：2843-2849.
[11] SCHUMANN G，BONORA R，CERIOTTI F，et al. IFCC primary reference procedures for the measurement of catalytic activity concentrations of enzymes at 37 degrees C. International federation of clinical chemistry and laboratory medicine. Part 4. Reference procedure for the measurement of catalytic concentration of alanine aminotransferase[J]. Clin Chem Lab Med，2002，40（7）：718-724.
[12] SCHUMANN G，BONORA R，CERIOTTI F，et al. IFCC primary reference procedures for the measurement of catalytic activity concentrations of enzymes at 37 degrees c. International federation of clinical chemistry and laboratory medicine. Part 5. Reference procedure for the measurement of catalytic concentration of aspartate aminotransferase[J]. Clin Chem Lab Med，2002，40（7）：725-733.
[13] RATZIU V，IMBERT-BISMUT F，MESSOUS D，et al. The elusiveness of “normal” ALT in fatty liver
[J]. Hepatology，2004，39（4）：1172-1172.
[14] PACIFICO L，FERRARO F，BONCI E，et al. Upper limit of normal for alanine aminotransferase: quo vadis?[J]. Clin Chim Acta，2013，422（6）：29-39.
[15] LORENZO C，HANLEY A J，REWERS M J，et al. The association of alanine aminotransferase within the normal and mildly elevated range with lipoproteins and apolipoproteins：the insulin resistance atherosclerosis study[J]. Diabetologia，2013，56（4）：746-757.
[16] SIDDIQUI S，STERLING K，LUKETIC A，et al. Association between high-normal levels of alanine aminotransferase and risk factors for atherogenesis[J]. Gastroenterology，2013，145（6）：1271-1279.
[17] SCHOOLING C M，KELVIN E A，JONES H E. Alanine transaminase has opposite associations with death from diabetes and ischemic heart disease in
NHANES Ⅲ[J]. Ann Epidemiol，2012，22（11）：789-798.
[18] DG LEC，COGGER V C，MCCUSKEY R S，et al. Age-related changes in the liver sinusoidal endothelium：a mechanism for dyslipidemia[J/OL]. Ann N Y Acad Sci，2007，1114：79-87[2022-06-03]. https://doi.org/10.1196/annals.1396.003.
[19] ONG M H，BETTENCOURT R，BRENNER D A，et al. Serum levels of alanine aminotransferase decrease with age in longitudinal analysis[J]. Clin Gastroenterol Hepatol，2012，10（3）：285-290.
[20] SCHMUCKER D L. Age-related changes in liver structure and function：Implications for disease?[J]. Exp Gerontol，2005，40（8/9）：650-659.
[21] LE COUTEUR D G，BLYTH F M，CREASEY H M，et al. The association of alanine transaminase with aging，frailty，and mortality[J]. J Gerontol A Biol Sci Med Sci，2010，65（7）：712-717.
[22] TARGHER G，DAY C P，BONORA E. Risk of cardiovascular disease in patients with nonalcoholic fatty liver disease[J]. N Engl J Med，2010，363（14）：1341-1350.
[23] IOANNOU G N. Implications of elevated serum alanine aminotransferase levels: think outside the liver[J]. Gastroenterology，2008，135（6）：1851-1854.
[24] CAMPOS F，RODRIGUEZ-YANEZ M，CASTELLANOS M，et al. Blood levels of glutamate oxaloacetate transaminase are more strongly associated with good outcome in acute ischaemic stroke than glutamate pyruvate transaminase levels[J]. Clin Sci，2011，121（1）：11-17.
[25] CAMPOS F，SOBRINO T，RAMOS-CABRER P，et al. High blood glutamate oxaloacetate transaminase levels are associated with good functional outcome in acute ischemic stroke[J]. J Cereb Blood Flow Metab，2011，31（6）：1387-1393.